Investors see a biotech comeback in 2024 as rates fall, deal-making picks up. Stocks to watch
Many biotech stocks struggled in 2023 despite a robust year for U.S. drug approvals. A look at what 2024 might have in store.
Source: cnbc.com
Stay updated with breaking news from Janu Lyons. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Many biotech stocks struggled in 2023 despite a robust year for U.S. drug approvals. A look at what 2024 might have in store.